Non-Vitamin K Oral Anticoagulants (NOAC) versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type
Why the study?
The study aimed to evaluate the benefits and risks of NOAC versus VKA combinations in patients undergoing PCI, with a particular focus on combination types across dual and triple antithrombotic therapies.
Does NOAC-based antithrombotic therapy reduce bleeding risk compared to VKA-based therapy in patients with atrial fibrillation undergoing PCI?
Comparison
NOAC vs VKA across dual vs dual, dual vs triple, and triple vs triple antithrombotic therapy
Design
Meta-analysis of randomized controlled trials
Authors
Discussion
Loading...
Member takes
Implication
NOAC regimens reduce major bleeding versus VKA without increasing ischemic events; reinforces DAT NOAC preference post-PCI in AF.
Structured PICO
Does NOAC-based antithrombotic therapy reduce bleeding risk compared to VKA-based therapy in patients with atrial fibrillation undergoing PCI?
P
Population
10,969 patients with atrial fibrillation undergoing elective or urgent percutaneous coronary intervention (PCI) from 4 randomized controlled trials (PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, and ENTRUST-AF PCI)
I
Intervention
Non-vitamin K oral anticoagulants (NOAC) as part of dual antithrombotic therapy (NOAC + single antiplatelet therapy) or triple antithrombotic therapy (NOAC + dual antiplatelet therapy)
C
Comparator
Vitamin K antagonists (VKA) as part of dual antithrombotic therapy (VKA + single antiplatelet therapy) or triple antithrombotic therapy (VKA + dual antiplatelet therapy)
O
Outcome
Composite of major bleeding defined by the International Society on Thrombosis and Hemostasis (ISTH) and clinically relevant non-major bleeding requiring medical intervention (CRNM)safety
In patients with atrial fibrillation undergoing PCI, NOAC-based antithrombotic combinations significantly reduce bleeding risk compared to VKA-based regimens without increasing ischemic or thrombotic events.
Cite This Study
Eyileten et al. (2020) studied this question.